［1］冉兴无.加强糖尿病周围血管病变的筛查与规范化管理.中华糖尿病杂志，2012，4（8）：449⁃451.

［2］冉兴无，郑月宏.加强多学科协作，提高糖尿病缺血性足溃疡的治愈率.中华糖尿病杂志，2016，8（7）：728⁃733.

［3］张斌，向红丁，毛微波，等.北京、上海、天津、重庆四城市住院2型糖尿病患者糖尿病慢性并发症及相关大血管疾病的流行病学分析.中国医学科学院学报，2002，24（5）：452⁃456.

［4］中华医学会糖尿病学分会糖尿病慢性并发症调查组.全国住院糖尿病患者慢性并发症及其相关危险因素10年回顾性调查分析.中国糖尿病杂志，2003，11（4）：232⁃237.

［5］Guan H，Li YJ，Xu ZR，et al.Prevalence and risk factors of peripheral arterial disease in diabetic patients over 50 years old in China.Chin Med Sci J，2007，22（2）：83⁃88.

［6］沈琴，贾伟平，包玉倩，等.社区糖尿病及糖调节受损人群周围血管病变的患病率调查.中华医学杂志，2006，86（22）：1530⁃1533.

［7］Jiang Y，Ran X，Jia L，et al.Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China.Int J Low Extrem Wounds，2015，14（1）：19⁃27.

［8］费扬帆，王椿，陈大伟，等.住院糖尿病足患者截肢率与截肢危险因素分析.中华医学杂志，2012，92（24）：1686⁃1689.

［9］Steg PG，Bhatt DL，Wilson PW，etal.One⁃year cardiovascular event rates in outpatientswith atherothrombosis.JAMA，2007，297（11）：1197⁃1206.

［10］Cang Y，Li J，Li YM，et al.Relationship of low ankle⁃brachial index with all⁃cause mortality and cardiovascular mortality in Chinese patientswith metabolic syndrome after a 6⁃year follow⁃up：a Chinese prospective cohort study.Intern Med，2012，51（20）：2847⁃2856.

［11］中华医学会糖尿病学分会.2型糖尿病患者合并下肢动脉病变的筛查及管理规范.中华糖尿病杂志，2013，5（2）：82⁃88.

［12］Thorud JC，Plemmons B，Buckley CJ，et al.Mortality After Nontraumatic Major Amputation Among PatientsWith Diabetes and Peripheral Vascular Disease：A Systematic Review.JFoot Ankle Surg，2016，55（3）：591⁃599.

［13］冉兴无.糖尿病周围动脉病变：一个处于灰区的危险状态.中华医学杂志，2012，92（4）：217⁃218.

［14］Hirsch AT，Murphy TP，Lovell MB，et al.Peripheral Arterial Disease Coalition.Gaps in public knowledge of peripheral arterial disease：the first national PAD public awareness survey.Circulation，2007，116（18）：2086⁃2094.

［15］Lovell M，Harris K，Forbes T，etal；Peripheral Arterial Disease Coalition.Peripheral arterial disease：lack ofawareness in Cana⁃da.Can JCardiol，2009，25（1）：39⁃45.

［16］Lange S，Diehm C，Darius H，etal.High prevalence of peripheralarterial disease and low treatment rates in elderly primary care patients with diabetes.Exp Clin Endocrinol Diabetes，2004，112（10）：566⁃573.

［17］Gibbons GW，Shaw PM.Diabetic vascular disease：characteristics of vascular disease unique to the diabetic patient.Semin Vasc Surg，2012，25（2）：89⁃92.

［18］Londero LS，Lindholt JS，Thomsen MD，et al.Pulse palpation is an effectivemethod for population⁃based screening to exclude peripheral arterial disease.JVasc Surg，2016，63（5）：1305⁃1310.

［19］Rooke TW，Hirsch AT，Misra S，et al.2011 Writing Group Members；2005 Writing Committee Members ACCF/AHA Task Force Members.2011 ACCF/AHA Focused Update of the Guideline for the Management of patientswith peripheral artery dis⁃ease（Updating the 2005 Guideline）：a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation，2011，124（18）：2020⁃2045.

［20］Hoe J，Koh WP，Jin A，et al.Predictors of decrease in ankle⁃brachial index among patientswith diabetesmellitus.DiabetMed，2012，29（9）：e304⁃e307.

［21］Dachun Xu，Jue Li，Liling Zou，et al.Sensitivity and specificity of the ankle⁃⁃brachial index to diagnose peripheral artery dis⁃ease：a structured review.Vasc Med，2010，15（5）：361⁃369.

［22］陈大伟，卢武胜，王椿，等.糖尿病足病患者踝肱指数和下肢动脉造影特点及其相关分析.四川大学学报（医学版），2010，41（4）：731⁃733.

［23］Brooks B，Dean R，Patel S，et al.TBIor not TBI：that is the question.Is it better tomeasure toe pressure than ankle pressure in diabetic patients？Diabet Med，2001，18（7）：528⁃532.

［24］中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013年版）.中华糖尿病杂志，2014，6（7）：447⁃498.

［25］Marso SP，HiattWR.Peripheral arterial disease in patients with diabetes.JAm Coll Cardiol，2006，47（5）：921⁃929.

［26］Alonso⁃Coello P，Bellmunt S，McGorrian C，et al；American College of Chest Physicians.Antithrombotic therapy in peripheral artery disease：Antithrombotic Therapy and Prevention of Thrombosis，9th ed：American College of Chest Physicians Evidence⁃Based Clinical Practice Guidelines.Chest，2012，141（2 Suppl）：e669S⁃90S.

［27］Feringa HH，van Waning VH，Bax JJ，et al.Cardioprotectivemedication is associated with improved survival in patients with peripheral arterial disease.JAm Coll Cardiol，2006，47（6）：1182⁃1187.

［28］Lane R，Ellis B，Watson L，et al.Exercise for intermittent claudication.Cochrane Database.Syst Rev，2014，（7）：CD000990.

［29］Lyu X，Li S，Peng S，et al.Intensive walking exercise for lower extremity peripheral arterial disease：A systematic review and meta⁃analysis.JDiabetes，2016，8（3）：363⁃377.

［30］Fokkenrood HJ，Bendermacher BL，Lauret GJ，et al.Supervised exercise therapy versus non⁃supervised exercise therapy for in⁃termittent claudication.Cochrane Database Syst Rev，2013，（8）：CD005263.

［31］Gardner AW，Parker DE，Montgomery PS，et al.Efficacy of quantified home⁃based exercise and supervised exercise in patients with intermittent claudication：a randomized controlled trial.Circulation，2011，123（5）：491⁃498.

［32］Müller⁃Bühl U，Engeser P，Leutgeb R，et al.Low attendance of patients with intermittent claudication in a German community⁃based walking exercise program.Int Angiol，2012，31（3）：271⁃275.

［33］Campbel l A，Price J，Hiatt WR.Omega⁃3 fatty acids for intermittent claudication.Cochrane Database Syst Rev，2013，（7）：CD003833.

［34］Berger JS，Krantz MJ，Kittelson JM，et al.Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease：ameta⁃analysis of randomized trials.JAMA，2009，301（18）：1909⁃1919.

［35］Wong PF，Chong LY，Mikhailidis DP，etal.Antiplateletagents for intermittent claudication.Cochrane Database SystRev，2011，（11）：CD001272.

［36］Bedenis R，Lethaby A，Maxwell H，et al.Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.Cochrane Database Syst Rev，2015，（2）：CD000535.

［37］Robertson L，GhouriMA，Kovacs F.Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following pe⁃ripheral endovascular treatment.Cochrane Database Syst Rev，2012，（8）：CD002071.

［38］Cosmi B，Conti E，Coccheri S.Anticoagulants（heparin，low molecular weight heparin and oral anticoagulants）for intermittent claudication.Cochrane Database Syst Rev，2014，（5）：CD001999.

［39］Berridge DC，Kessel DO，Robertson I.Surgery versus thrombolysis for initialmanagementof acute limb ischaemia.Cochrane Da⁃tabase Syst Rev，2013，（6）：CD002784.

［40］Kumbhani DJ，Steg PG，Cannon CP，et al；REACH Registry Investigators.Statin therapy and long⁃term adverse limb outcomes in patientswith peripheral artery disease：insights from the REACH registry.Eur Heart J，2014，35（41）：2864⁃2872.

［41］Antoniou GA，Fisher RK，Georgiadis GS，et al.Statin therapy in lower limb peripheral arterial disease：Systematic review and meta⁃analysis.Vascul Pharmacol，2014，63（2）：79⁃87.

［42］Ramos R，García⁃Gil M，Comas⁃CufíM，et al.Statins for Prevention of Cardiovascular Events in a Low⁃Risk Population With Low Ankle Brachial Index.JAm Coll Cardiol.2016，67（6）：630⁃640.

［43］Ostergren J，Sleight P，Dagenais G，et al.HOPE study investigators.Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease.Eur Heart J，2004，25（1）：17⁃24.

［44］Ahimastos AA，Walker PJ，Askew C，etal.Effectof ramipril on walking times and quality of life among patientswith peripheral artery disease and intermittent claudication：a randomized controlled trial.JAMA，2013，309（5）：453⁃460.

［45］Zankl AR，Ivandic B，Andrassy M，et al.Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease.Clin Res Cardiol，2010，99（12）：787⁃94.

［46］Shahin Y，Barnes R，Barakat H，et al.Meta⁃analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication.Atherosclerosis，2013，231（2）：283⁃290.

［47］Paravastu SC，Mendonca DA，Da Silva A.Beta blockers for peripheral arterial disease.Cochrane Database Syst Rev，2013，（9）：CD005508.

［48］Diehm C，Pittrow D，Lawall H.Effect of nebivolol vs.hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication.JHypertens，2011，29（7）：1448⁃1456.

［49］Armstrong EJ，Chen DC，Westin GG，etal.Adherence to guideline⁃recommended therapy is associated with decreasedmajor ad⁃verse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.JAm Heart Assoc，2014，3（2）：e000697.

［50］Hasimu B，Li J，Yu J，et al.Evaluation ofmedical treatment for peripheral arterial disease in Chinese high⁃risk patients.Circ J，2007，71（1）：95⁃99.

［51］Robertson L，Andras A.Prostanoids for intermittent claudication.Cochrane Database Syst Rev，2013，（4）：CD000986.

［52］Vitale V，MonamiM，Mannucci E.Prostanoids in patientswith peripheral arterial disease：Ameta⁃analysis of placebo⁃controlled randomized clinical trials.JDiabetes Complications.2016，30（1）：161⁃166.

［53］Yoon HS，ChoiWJ，Sung IH，etal.Effects of Beraprost sodium on subjective symptoms in diabetic patientswith peripheralarte⁃rial disease.Clin Orthop Surg，2013，5（2）：145⁃151.

［54］Lièvre M，Morand S，Besse B，etal.Oral Beraprostsodium，a prostaglandin I（2）analogue，for intermittent claudication：a doub⁃le⁃blind，randomized，multicenter controlled trial.Beraprostet Claudication Intermittente（BERCI）Research Group.Circulation，2000，102（4）：426⁃431.

［55］　Mohler ER，Hiatt WR，Olin JW，et al.Treatment of intermittent claudication with beraprost sodium，an orally active prostaglandin I2 analogue：a double⁃blinded，randomized，controlled trial.JAm Coll Cardiol，2003，41（10）：1679⁃1686.

［56］O’Donnell ME，Badger SA，SharifMA，etal.The vascular and biochemical effects of cilostazol in diabetic patientswith periph⁃eral arterial disease.Vasc Endovascular Surg，2009，43（2）：132⁃143.

［57］Bedenis R，Stewart M，Cleanthis M，et al.Cilostazol for intermittent claudication.Cochrane Database Syst Rev，2014，（10）：CD003748.

［58］高伟，王芳，刘关键，等.盐酸沙格雷酯治疗周围动脉疾病疗效与安全性的系统评价.中国循证医学杂志，2012，12（3）：341⁃346.

［59］中华医学会糖尿病学分会.中华医学会糖尿病学分会关于干细胞移植治疗糖尿病下肢动脉病变的立场声明.中华糖尿病杂志，2010，2（6）：404⁃409.